$SWTX
SpringWorks Therapeutics, Inc. Stock $swtx

$swtx Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000177342724000033 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$49.30M	$0.00
YoY Change
Cost Of Revenue		$3.341M	$0.00
YoY Change
Gross Profit		$45.96M	$0.00
YoY Change
Gross Profit Margin		93.22%
Selling, General & Admin		$61.60M	$46.55M
YoY Change		32.33%	30.49%
% of Gross Profit		134.03%
Research & Development		$42.30M	$37.45M
YoY Change		12.93%	3.84%
% of Gross Profit		92.03%
Depreciation & Amortization		$878.0K	$490.0K
YoY Change		79.18%	131.13%
% of Gross Profit		1.91%
Operating Expenses		$103.9M	$84.00M
YoY Change		23.69%	17.09%
Operating Profit		-$57.94M	-$84.00M
YoY Change		-31.03%	17.09%
Interest Expense		$4.407M	$4.640M
YoY Change		-5.02%	-908.36%
% of Operating Profit
Other Income/Expense, Net		$6.216M	$5.586M
YoY Change		11.28%	566.59%
Pretax Income		-$53.53M	-$79.44M
YoY Change		-32.62%	9.74%
Income Tax
% Of Pretax Income
Net Earnings		-$53.53M	-$79.44M
YoY Change		-32.61%	9.74%
Net Earnings / Revenue		-108.58%
Basic Earnings Per Share		-$0.72	-$1.27
Diluted Earnings Per Share		-$0.72	-$1.27
COMMON SHARES
Basic Shares Outstanding	74.39M shares	74.27M shares	62.57M shares
Diluted Shares Outstanding		74.26M shares	62.52M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$376.6M	$422.4M
YoY Change	-10.84%	-35.21%
Cash & Equivalents	$84.46M	$98.90M
Short-Term Investments	$292.2M	$323.5M
Other Short-Term Assets	$15.69M	$10.00M
YoY Change	56.94%	87.13%
Inventory	$9.826M
Prepaid Expenses
Receivables	$32.97M
Other Receivables	$0.00
Total Short-Term Assets	$435.1M	$432.4M
YoY Change	0.63%	-34.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.34M	$20.92M
YoY Change	-7.59%	82.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$5.580M	$3.789M
YoY Change	47.27%	-22.25%
Other Assets	$20.70M	$3.483M
YoY Change	494.32%	41.99%
Total Long-Term Assets	$173.8M	$35.27M
YoY Change	392.66%	45.35%
TOTAL ASSETS
Total Short-Term Assets	$435.1M	$432.4M
Total Long-Term Assets	$173.8M	$35.27M
Total Assets	$608.9M	$467.7M
YoY Change	30.2%	-31.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.654M	$5.546M
YoY Change	74.07%	20.93%
Accrued Expenses	$59.73M	$40.33M
YoY Change	48.1%	2.65%
Deferred Revenue	$0.00	$3.244M
YoY Change	-100.0%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$70.61M	$50.28M
YoY Change	40.43%	1.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$5.684M	$22.50M
YoY Change	-74.74%	53.48%
Total Long-Term Liabilities	$5.684M	$22.50M
YoY Change	-74.74%	53.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$70.61M	$50.28M
Total Long-Term Liabilities	$5.684M	$22.50M
Total Liabilities	$76.30M	$72.76M
YoY Change	4.87%	5.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.076B	-$800.7M
YoY Change	34.37%	61.5%
Common Stock	$7.000K	$6.000K
YoY Change	16.67%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$532.6M	$394.9M
YoY Change
Total Liabilities & Shareholders Equity	$608.9M	$467.7M
YoY Change	30.2%	-31.38%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$53.53M	-$79.44M
YoY Change	-32.61%	9.74%
Depreciation, Depletion And Amortization	$878.0K	$490.0K
YoY Change	79.18%	131.13%
Cash From Operating Activities	-$25.38M	-$50.46M
YoY Change	-49.7%	157.4%
INVESTING ACTIVITIES
Capital Expenditures	$1.847M	$3.620M
YoY Change	-48.98%	-202.61%
Acquisitions
YoY Change
Other Investing Activities	$30.50M	$38.22M
YoY Change	-20.21%	-57.42%
Cash From Investing Activities	$28.65M	$34.60M
YoY Change	-17.2%	-59.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.291M	-240.0K
YoY Change	-637.92%	-100.07%
NET CHANGE
Cash From Operating Activities	-25.38M	-50.46M
Cash From Investing Activities	28.65M	34.60M
Cash From Financing Activities	1.291M	-240.0K
Net Change In Cash	4.560M	-16.10M
YoY Change	-128.32%	-103.96%
FREE CASH FLOW
Cash From Operating Activities	-$25.38M	-$50.46M
Capital Expenditures	$1.847M	$3.620M
Free Cash Flow	-$27.23M	-$54.08M
YoY Change	-49.66%	236.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001773427
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	SPRINGWORKS THERAPEUTICS, INC.
	dei	Trading Symbol TradingSymbol	SWTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	us-gaap	Net Income Loss NetIncomeLoss	-230782000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-180834000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-53530000	usd
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74386403	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84456000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	176053000	usd
CY2024Q3	us-gaap	Marketable Securities MarketableSecurities	292163000	usd
	dei	Entity Address City Or Town EntityAddressCityOrTown	Stamford
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06902
	dei	City Area Code CityAreaCode	203
	dei	Local Phone Number LocalPhoneNumber	883-9490
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	303149000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4610000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3203000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7915000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2547000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12025000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	115000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4110000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2432000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-91589000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1100000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-895000000.0	usd
CY2024Q3	swtx	Working Capital WorkingCapital	364500000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-180834000	usd
	us-gaap	Depreciation Depreciation	2451000	usd
	us-gaap	Depreciation Depreciation	1129000	usd
	swtx	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	1523000	usd
	swtx	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	1176000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	82670000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	69467000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	137715000	usd
CY2024Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	121504000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	183386000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19336000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17943000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#ProductMember
CY2023Q3	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#ProductMember
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	32972000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5930000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	500912000	usd
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	12056000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	4141000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1607000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	613000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9654000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7396000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59733000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	76297000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	99569000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74663748	shares
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1075868000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-895034000	usd
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	194807	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	133662	shares
	dei	Entity File Number EntityFileNumber	001-39044
	dei	Document Type DocumentType	10-Q
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2024Q3	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#ProductMember
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6144000	usd
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#ProductMember
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Washington Blvd
CY2023Q4	us-gaap	Inventory Net InventoryNet	3103000	usd
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-4066827
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1191000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15694000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12677000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6026000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14835000	usd
CY2023Q4	us-gaap	Assets Assets	725788000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4144000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	70613000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	49301000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5684000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5996000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73486699	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	532581000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	9826000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42296000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	435111000	usd
CY2024Q3	us-gaap	Equity Method Investments EquityMethodInvestments	5580000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1955000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20700000	usd
CY2024Q3	us-gaap	Assets Assets	608878000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	65569000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1226000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1061000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	78170000	usd
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74335279	shares
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	usd
CY2024Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	usd
CY2023Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	usd
CY2024Q3	us-gaap	Revenues Revenues	49301000	usd
CY2023Q3	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	130040000	usd
	us-gaap	Revenues Revenues	0	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3341000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61601000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	46546000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	179553000	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	621000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	110493000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	15403000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73620361	shares
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1618891000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6996000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	19547000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1524196000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	626219000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	608878000	usd
CY2024Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	107238000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	725788000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37453000	usd
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	83999000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	140280000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	326829000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	106835000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	244550000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-57937000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-83999000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-196789000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-244550000	usd
CY2024Q3	us-gaap	Investment Income Net InvestmentIncomeNet	6216000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	20565000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	16971000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6216000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5586000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16971000	usd
CY2024Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1809000	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1024000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-79437000	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.70
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.70
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74264501	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74264501	shares
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3203000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74052151	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74052151	shares
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-53530000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-79437000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-230782000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2127000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	39000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	416000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	454000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2127000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	39000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	416000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	454000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-79398000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-180418000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	451441000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-180834000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-230328000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23099000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000	usd
CY2023Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	264000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	39000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-79437000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	394899000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-230782000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25963000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1790000	usd
CY2024Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	499000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2127000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	532581000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	558192000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	69467000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	394899000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6723000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3017000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2416000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1298000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	686000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2261000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1943000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-19547000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
	swtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-1552000	usd
	swtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-863000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-146099000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3399000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9687000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11250000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	8235000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	2800000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	309276000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	277541000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-230782000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	626219000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7915000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	416000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	27042000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1940000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-53530000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2547000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68068000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	454000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	82670000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	515722000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	50400000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	193959000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	176666000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	720000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	532581000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-160090000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	662600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-180834000	usd
CY2023Q4	swtx	Working Capital WorkingCapital	422700000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	115000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12025000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25963000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85077000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99505000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	877000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2637000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	498100000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	412060000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1607000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	413667000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1191000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2024Q3	swtx	Equity Method Investments Purchase Obligation Value EquityMethodInvestmentsPurchaseObligationValue	12400000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	82670000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of Operations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SpringWorks Therapeutics, Inc., together with its wholly-owned subsidiaries, collectively, the Company, is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The Company has a differentiated portfolio of small molecule targeted oncology assets, including one approved product, one product candidate under regulatory review for approval, and several clinical candidates, and is advancing programs in both rare tumor types as well as highly prevalent, genetically defined cancers. OGSIVEO® (nirogacestat) is the Company’s first commercial product. OGSIVEO was approved by the United States Food and Drug Administration, or FDA, on November 27, 2023 for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative operating cash flows since inception and had an accumulated deficit of $1.1 billion and $895.0 million, and working capital of $364.5 million and $422.7 million, as of September 30, 2024 and December 31, 2023, respectively. For the three and nine months ended September 30, 2024, the Company recorded net product revenue of $49.3 million and $110.5 million, respectively, from sales of OGSIVEO.</span></div>The Company had cash, cash equivalents and marketable securities of $498.1 million and $662.6 million as of September 30, 2024 and December 31, 2023, respectively. Based on the Company’s cash, cash equivalents and marketable securities as of September 30, 2024, management estimates that its current liquidity will enable it to meet operating expenses through at least twelve months after the date that these financial statements are issued.
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15231323	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13402403	shares
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	486535000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20311000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	26047000	usd
CY2024Q3	swtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	14223000	usd
CY2023Q4	swtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	15129000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20199000	usd
CY2023Q4	swtx	Accrued Milestone AccruedMilestone	11250000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13143000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59733000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23099000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	69467000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Investment Income Net InvestmentIncomeNet	5586000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	20565000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4610000	usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.27
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.27
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.44
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62521772	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62521772	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62386496	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62386496	shares
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51403000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	556730000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	204257000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31437000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses, valuation of equity-based compensation awards and variable consideration and other relevant inputs impacting the gross to net revenue recognition adjustments. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known.</span></div>
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	485344000	usd
CY2024Q3	swtx	Accrued Milestone AccruedMilestone	5000000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	65569000	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	usd
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001773427-24-000033-index-headers.html	Edgar Link	pending
0001773427-24-000033-index.html	Edgar Link	pending
0001773427-24-000033.txt	Edgar Link	pending
0001773427-24-000033-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
swtx-20240930.htm	Edgar Link	pending
swtx-20240930.xsd	Edgar Link	pending
swtx-20240930xex311.htm	Edgar Link	pending
swtx-20240930xex312.htm	Edgar Link	pending
swtx-20240930xex321.htm	Edgar Link	pending
swtx-20240930xex322.htm	Edgar Link	pending
swtx-20240930_cal.xml	Edgar Link	unprocessable
swtx-20240930_def.xml	Edgar Link	unprocessable
swtx-20240930_lab.xml	Edgar Link	unprocessable
swtx-20240930_pre.xml	Edgar Link	unprocessable
swtx-20240930_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SWTX
SpringWorks Therapeutics, Inc. Stock $swtx

2024 Q4 Form 10-Q Financial Statement

#000177342724000033 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWTX SpringWorks Therapeutics, Inc. Stock $swtx

2024 Q4 Form 10-Q Financial Statement

#000177342724000033 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWTX
SpringWorks Therapeutics, Inc. Stock $swtx